These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 34100836)

  • 61. Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapy.
    Lefebvre C; Martin E; Hendriks LEL; Veillon R; Puisset F; Mezquita L; Ferrara R; Sabatier M; Filleron T; Dingemans AC; Besse B; Raherisson C; Mazières J
    Respir Med Res; 2020 Nov; 78():100788. PubMed ID: 32980653
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Validation of the American Joint Committee on Cancer Eighth Edition Staging of Patients With Metastatic Cutaneous Melanoma Treated With Immune Checkpoint Inhibitors.
    Waninger JJ; Ma VT; Journey S; Skvarce J; Chopra Z; Tezel A; Bryant AK; Mayo C; Sun Y; Sankar K; Ramnath N; Lao C; Sussman JB; Fecher L; Alva A; Green MD
    JAMA Netw Open; 2021 Mar; 4(3):e210980. PubMed ID: 33687443
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China.
    Zhang X; Zeng L; Li Y; Xu Q; Yang H; Lizaso A; Mao X; Jin R; Zeng Y; Li Q; Wang J; Li Y; Zhang Y; Yang N
    Cancer Immunol Immunother; 2021 Sep; 70(9):2517-2528. PubMed ID: 33566148
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Immune checkpoint inhibitor-associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation.
    Chanson N; Ramos-Casals M; Pundole X; Suijkerbuijk K; José de Barros E Silva M; Lidar M; Benesova K; Leipe J; Acar-Denizli N; Pradère P; Michot JM; Voisin AL; Suárez-Almazor ME; Radstake TRD; Fernandes Moça Trevisani V; Schulze-Koops H; Melin A; Robert C; Mariette X; Baughman RP; Lambotte O; ; ; ; ; ;
    Eur J Cancer; 2021 Nov; 158():208-216. PubMed ID: 34452793
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Case Report: Antiangiogenic Therapy Plus Immune Checkpoint Inhibitors Combined With Intratumoral Cryoablation for Hepatocellular Carcinoma.
    Li X; Xu J; Gu X; Chen L; Wu Q; Li H; Bai H; Yang J; Qian J
    Front Immunol; 2021; 12():740790. PubMed ID: 34733279
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma.
    Leidner R; Crittenden M; Young K; Xiao H; Wu Y; Couey MA; Patel AA; Cheng AC; Watters AL; Bifulco C; Morris G; Rushforth L; Nemeth S; Urba WJ; Gough M; Bell RB
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963014
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer.
    Schvartsman G; Peng SA; Bis G; Lee JJ; Benveniste MFK; Zhang J; Roarty EB; Lacerda L; Swisher S; Heymach JV; Fossella FV; William WN
    Lung Cancer; 2017 Oct; 112():90-95. PubMed ID: 29191606
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Marjolin's ulcer: a rare entity with a call for early diagnosis.
    Iqbal FM; Sinha Y; Jaffe W
    BMJ Case Rep; 2015 Jul; 2015():. PubMed ID: 26177995
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Successful management of in-transit cutaneous squamous cell carcinoma with anti-PD-1 immunotherapy.
    Furkert C; Martin R; Sharma A; Rivalland G
    World J Surg Oncol; 2023 Sep; 21(1):291. PubMed ID: 37715254
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Clinical outcomes among unresectable, locally advanced, and metastatic cutaneous squamous cell carcinoma patients treated with systemic therapy.
    Cowey CL; Robert NJ; Espirito JL; Davies K; Frytak J; Lowy I; Fury MG
    Cancer Med; 2020 Oct; 9(20):7381-7387. PubMed ID: 32578965
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Marjolin Ulcer: An Observational Epidemiological Study From a Tertiary Care Centre in India.
    Chaturvedi G; Gupta AK; Das S; Gohil AJ; Lamba S
    Ann Plast Surg; 2019 Nov; 83(5):518-522. PubMed ID: 31567416
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Real-world efficacy of atezolizumab in non-small cell lung cancer: A multicenter cohort study focused on performance status and retreatment after failure of anti-PD-1 antibody.
    Furuya N; Nishino M; Wakuda K; Ikeda S; Sato T; Ushio R; Tanzawa S; Sata M; Ito K
    Thorac Cancer; 2021 Mar; 12(5):613-618. PubMed ID: 33448648
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Computed tomography-guided biopsy of radiologically unclear lesions in advanced skin cancer: A retrospective analysis of 47 cases.
    Franklin C; Wetter A; Baba HA; Theysohn J; Haubold J; Cosgarea I; Hadaschik E; Livingstone E; Zimmer L; Stoffels I; Klode J; Lodde G; Placke JM; Schadendorf D; Ugurel S
    Eur J Cancer; 2021 Jun; 150():119-129. PubMed ID: 33895683
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma.
    Hernández-Guerrero T; Doger B; Moreno V
    Drugs Today (Barc); 2019 Aug; 55(8):485-494. PubMed ID: 31461085
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Evaluating Predictors of Immune-Related Adverse Events and Response to Checkpoint Inhibitors in Myeloid Malignancies.
    Gesiotto QJ; Swoboda DM; Shallis RM; Al Ali N; Padron E; Kuykendall AT; Song J; Talati C; Sweet K; Lancet JE; Zeidan AM; Komrokji RS; Sallman DA
    Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):421-424.e2. PubMed ID: 33583730
    [No Abstract]   [Full Text] [Related]  

  • 76. Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.
    Arrieta O; Barrón F; Ramírez-Tirado LA; Zatarain-Barrón ZL; Cardona AF; Díaz-García D; Yamamoto Ramos M; Mota-Vega B; Carmona A; Peralta Álvarez MP; Bautista Y; Aldaco F; Gerson R; Rolfo C; Rosell R
    JAMA Oncol; 2020 Jun; 6(6):856-864. PubMed ID: 32271354
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Clinical research on the expression of three vascular regulatory factors in different morphological regions of Marjolin ulcer and their relationship with angiogenesis].
    Xia C; Chu ZG
    Zhonghua Shao Shang Za Zhi; 2019 Sep; 35(9):676-682. PubMed ID: 31594186
    [No Abstract]   [Full Text] [Related]  

  • 78. FDG-PET/CT imaging for evaluating durable responses to immune check point inhibitors in patients with advanced cutaneous squamous cell carcinoma.
    McLean LS; Cavanagh K; Hicks RJ; Callahan J; Xie J; Cardin A; Lim AM; Rischin D
    Cancer Imaging; 2021 Oct; 21(1):57. PubMed ID: 34645517
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or 
Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].
    Li H; Qin N; Yu M; Ma L; Wu Y; Zhang H; Zhang X; Li X; Wang J
    Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):161-166. PubMed ID: 33819965
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Multimodality management of locoregionally extensive Marjolin ulcer: a case report and review of the literature.
    Mitra S; Panda S; Sikka K; Mallick S; Thakar A
    Wounds; 2024 May; 36(5):166-169. PubMed ID: 38861212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.